NEW YORK - Immunocore ya fada a ranar Litinin cewa zai sayar da hannun jari na 3,733,333 a cikin yarjejeniyar zuba jari mai zaman kanta (PIPE) da ake sa ran za ta tara dala miliyan 140.
A karkashin yarjejeniyar, Immunocore zai sayar da hannun jarinsa na gama-gari da kuma wanda ba na kada kuri'a ba akan dala 37.50 a kowace rabon. Masu zuba jari na kamfanin da ke shiga cikin kudaden sun hada da RTW Investments, Rock Springs Capital da General Atlantic. Ana sa ran yarjejeniyar PIPE za ta ƙare a ranar 20 ga Yuli.
Kamfanin zai yi amfani da kudaden da aka samu don tallafawa 'yan takarar bututun cutar kanjamau, gami da haɓaka ɗan takararsa na jagorar oncology, Kimmtrak (tebentafusp-tebn), don kula da HLA-A * 02: 01 tabbatacce fata da uveal melanoma. Ana sa ran kuɗin, tare da kudaden shiga daga Kimmtrak, za su ba da gudummawar ayyukan Immunocore ta hanyar ayyukan 2202.
A wannan shekara, Kimmtrak an yarda da shi don amfani da marasa lafiya tare da HLA-A * 02: 01 tabbatacce wanda ba a iya daidaita shi ba ko metastatic uveal melanoma a cikin Amurka, Turai da Birtaniya, a tsakanin sauran ƙasashe.
Har ila yau, Immunocore yana haɓaka wasu 'yan takarar oncology guda huɗu, ciki har da ƙarin magunguna masu karɓa na T-cell guda biyu a cikin gwaje-gwaje na Phase I / II a cikin ci gaba da ciwace-ciwacen ciwace-ciwacen ciwace-ciwace.Daya daga cikin magungunan ana haɓakawa don HLA-A * 02: 01-tabbatacce da MAGE-A4-tabbatacce marasa lafiya, da sauran hari HLA-A * 02: 01 da kuma PRAME-tabbatacce ciwace-ciwacen daji na da ciwace-ciwacen ƙwayoyi biyu.
Manufofin Sirri.Sharuɗɗa da Sharuɗɗa.Haƙƙin mallaka © 2022 GenomeWeb, rukunin kasuwanci na Crain Communications.dukkan haƙƙin mallaka.